Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...

Bayer BAYN-0.85%decrease; red down pointing triangle said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer, a win for ...

In the United States, Bayer will continue its multipronged strategy to significantly contain the Roundup™ litigation. Having achieved favorable outcomes in 15 of the last 22 trials, the company ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains weak, with anticipated declining earnings. Consensus estimates project $3-4 billion free cash flow for 2026-2027 ...